Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTRLZHP)

• DTT Name: cAMP-dependent chloride channel (CFTR) DTT Info
• Gene Name: CFTR

Molecule-Related Drug & Molecule List

3 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Crofelemer	DM4AMQZ	HIV-associated diarrhoea	1A2Z	Approved	[1]
Ivacaftor	DMZC1HS	Cystic fibrosis	CA25	Approved	[2]
Tezacaftor and ivacaftor	DMY62FC	Acute lung injury	NB32.3	Approved	[3]

10 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
VX-661	DMJBXO3	Cystic fibrosis	CA25	Phase 3	[4]
ABBV-2222	DM4ZLTY	Cystic fibrosis	CA25	Phase 2	[5]
GLPG-1837	DMOCRYB	Cystic fibrosis	CA25	Phase 2	[5]
iOWH032	DM5TMYC	Diarrhea	ME05.1	Phase 2	[6]
Lumacaftor	DMCLWDJ	Cystic fibrosis	CA25	Phase 2	[7]
QBW251	DMQ5APT	Chronic obstructive pulmonary disease	CA22	Phase 2	[8]
ABBV-2451	DMUCF9L	Cystic fibrosis	CA25	Phase 1	[5]
ABBV-2737	DMU6K37	Cystic fibrosis	CA25	Phase 1	[5]
ABBV-3067	DMB01L5	Cystic fibrosis	CA25	Phase 1	[5]
VX-522	DMO1D9E	Cystic fibrosis	CA25	Phase 1	[9]

8 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CBIQ	DMDIW1M	Discovery agent	N.A.	Investigative	[10]
CFTRinh-172	DM8TJW3	Discovery agent	N.A.	Investigative	[10]
GlyH-101	DM67FQ1	Discovery agent	N.A.	Investigative	[10]
phenylglycine-01	DMHT9AR	Discovery agent	N.A.	Investigative	[10]
sulfonamide-01	DMU0BW9	Discovery agent	N.A.	Investigative	[10]
UCCF-029	DMO9S5P	Discovery agent	N.A.	Investigative	[10]
UCCF-339	DM3I9JG	Discovery agent	N.A.	Investigative	[10]
UCCF-853	DMN9QO4	Discovery agent	N.A.	Investigative	[10]

References

• [1] Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [3] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [4] CFTR Modulators for the Treatment of Cystic Fibrosis. P T. 2014 Jul;39(7):500-11.
• [5] Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
• [6] Developing novel antisecretory drugs to treat infectious diarrhea. Future Med Chem. 2011 Aug;3(10):1317-25.
• [7] A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir Med. 2014 Jul;2(7):527-38.
• [8] Safety and efficacy of the cystic fibrosis transmembrane conductance regulator potentiator icenticaftor (QBW251). J Cyst Fibros. 2021 Mar;20(2):250-256.
• [9] Clinical pipeline report, company report or official report of Vertex
• [10] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 707).